Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 21, 2012

Bend, Catalent to Offer Complex Oral Drug Formulation Services

  • Drug formulation and delivery specialists Bend Research and Catalent Pharma Solutions inked an agreement to pool their expertise and offer integrated solutions for the development and manufacture of specialized multiparticulate oral controlled-release products. The firms are instigating joint operations and technology transfer protocols to provide a more seamless process for clients.

    Bend Research offers an integrated pharmaceutical development services and solutions founded on expertise in formulation science, dosage form development, process development and engineering, cGMP production, biotherapeutics, and analytics. Catalent specializes in drug and biologics development services, drug delivery technologies including oral, injectable, and respiratory dosage forms, and supply solutions.

    Commenting on the Bend-Catalent partnership, Bend CEO Rod Ray said the firms’ combined expertise will facilitate the efficient development of complex, multiparticulate controlled-release products, “which traditionally have presented a high scale-up risk when they are transferred to commercial manufacturing sites.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »